Expert Opinion Report on the Challenges in the Management of Psoriatic Arthritis in United Arab Emirates: A Focus on Interleukin-17 Inhibitors
Year: 2025
Type: article
Abstract: Ahmed Abogamal,1 Humeira Badsha,2 Suad Hannawi,3 Ghita Harifi,4 Bhavna Khan,2 Atheer Al Ansari,5 Khalid A Alnaqbi,6,7 Ahmed S Zayat,8 Shady Ibrahim,9 Mohamed Taher,9 Rajaie Namas10 1Rheumatology Department, Al-Azhar University and Zahra Hospital Dubai, Dubai, United Arab Emirates; 2Rheumatology Department, HBG Medical Centre, Dubai, United Arab Emirates; 3Rheumatology Department, Al Kuwait Hospital, Emirates Health Services (EHS), Dubai, United Arab Emirates; 4Rheumatology Department, Kings College Hospital & Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Dubai, United Arab Emirates; 5Rheumatology Department, Mediclinic Airport Road Hospital, Abu Dhabi, United Arab Emirates; 6Rheumatology Division, Sheikh Tahnoon Medical City, SEHA/Purehealth, Al Ain, United Arab Emirates; 7Internal Medicine Department, College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates; 8Rheumatology Department, University Hospital Sharjah, University of Sharjah, Sharjah, United Arab Emirates; 9Rheumatology Department, Eli Lilly, Dubai, United Arab Emirates; 10Rheumatology Department, Cleveland Clinic, Abu Dhabi, United Arab EmiratesCorrespondence: Rajaie Namas, Cleveland Clinic Abu Dhabi, 59 Hamouda Bin Ali Al Dhaheri St, Al Maryah Island, Abu Dhabi Global Market Square, Abu Dhabi, United Arab Emirates, Email [email protected] Shady Ibrahim, Eli Lilly (Suisse) S.A., P.O. Box 25319, Dubai, United Arab Emirates, Tel +971551235113, Email [email protected]: To seek recommendations from a panel of experts in psoriatic arthritis (PsA) on the current management challenges, local practices, and role of interleukin (IL)-17 inhibitors in the United Arab Emirates (UAE) using evidence from phase III trials as background.Methods: Nine rheumatologists who treat PsA in the UAE completed a structured survey and attended a meeting to discuss topics/issues identified in the survey. A literature search was performed to identify phase III randomized trials of IL-17 inhibitors available in the UAE for PsA.Results: There was general agreement among the panel on the most common PsA domains presenting in patients (most commonly psoriasis [75– 95% of patients], peripheral arthritis [50– 90%], and enthesitis [40– 90%]). In general, IL-17 inhibitors were among the preferred treatment options for managing PsA, particularly for patients with axial-, enthesitis-, or psoriasis-related symptoms. Current unmet needs and challenges included a lack of disease awareness among the general population and other healthcare professionals; the lack of a single medication to cover all domains/comorbidities; and lack of universal insurance coverage. The panel had experienced success with the IL-17 inhibitors ixekizumab and secukinumab, with many citing no preference for either agent. The literature search identified publications relating to 10 key phase III clinical trials of IL-17 inhibitors.Conclusion: The panel advocates for the use of the domain-based Group for Research and Assessment of Psoriasis and Psoriatic Arthritis treatment recommendations and generally considers IL-17 inhibitors (ixekizumab or secukinumab) as the preferred treatment options for managing PsA.Keywords: ixekizumab, practice patterns, physicians’, secukinumab
Authors: Abogamal A, Badsha H, Hannawi S, Harifi G, Khan B, Ansari AA, Alnaqbi KA, Zayat AS, Ibrahim S, Taher M, Namas R
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7094976889
FWCI:
Cites:
Cited by:
Related to: